Please provide your email address to receive an email when new articles are posted on . “We believe that these results are quite powerful and informative,” Christopher Seder, MD, thoracic surgeon at ...
LOS ANGELES -- Surgeries to remove small tumors in stage IA non-small cell lung cancer (NSCLC) were associated with varying odds of long-term survival depending on the amount of lung removed, based on ...
For years, the default definitive treatment for patients with early-stage I non–small cell lung cancer (NSCLC) has been surgical resection, typically minimally invasive lobectomy with systematic lymph ...
Non-small cell lung cancer (NSCLC) remains the most prevalent type of lung cancer and a leading cause of cancer-related mortality worldwide. Surgical ...
Assessment of survival benefit with immunotherapy in combination with adjuvant chemoradiation in pathologic stage II-IIIB non-small cell lung cancer. Adjuvant icotinib of 12 months versus observation ...
PTNB before surgery in stage 1 NSCLC patients is linked to higher local-regional recurrence and mortality rates. The study included 2026 patients, with 38.6% undergoing PTNB, showing higher recurrence ...
Sample management algorithm for average-risk patients. A. Resection suggested over stereotactic body radiotherapy or ablative techniques. B. Resection by a board-certified thoracic surgeon suggested.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback